Oligodendrogliomas Recruiting Phase 2 Trials for Tislelizumab (DB14922)

Back to Oligodendrogliomas

Also known as: Oligodendroglioma of Brain / Oligodendroglioma / Oligodendroglioma - category (morphologic abnormality) / Oligodendroglioma (morphologic abnormality) / [M]Oligodendroglioma NOS (morphologic abnormality)

IndicationStatusPhase
DBCOND0032978 (Oligodendrogliomas)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05512351Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse OligodendrogliomaTreatment